<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="472">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <actrnumber>ACTRN12605000382673</actrnumber>
  <trial_identification>
    <studytitle>The effect of heated humidification on the compliance and reported satisfaction of patients with obstructive sleep apnea. (TS-KLINa)</studytitle>
    <scientifictitle>The effect of optimal heated humidification in conjunction with Continuous Positive Airway Pressure (CPAP) on the compliance and reported satisfaction of patients with obstructive sleep apnea. (TS-KLINa)</scientifictitle>
    <utrn />
    <trialacronym>TS-KLINa</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive Sleep Apnea</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Participants will be randomised to receive either a conventional humidifier or a novel humidifier (a humidifier that is capable of delivering a higher level of humidity than is typically delivered by a conventional humidifier.) for 4 weeks. 

At the end of 4 weeks participants will be swapped to the alternative humidifier for a further 4 weeks.

Duration:  8 weeks (2 4-week treatment arms)
Patient compliance and satisfaction with their treatment will be assessed.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Compliance</outcome>
      <timepoint>At weeks 4 and 8</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Subjective Comfort</outcome>
      <timepoint>Weeks 4 and 8</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. RDI &gt; 15 </inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Severe cardiac disease2. Chronic pulmonary disease3. Significant psychiatric illness.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>computer generated randomization sequence</concealment>
    <sequence>Randomisation sequence generated using computer software (Excel), and allocation stratified by site, place of residence and pre-fracture Barthel Index Score</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>5/01/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Fisher and Paykel Healthcare</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Fisher and Paykel Healthcare</fundingname>
      <fundingaddress />
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>NA</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Georgina Cuttance</name>
      <address>Fisher and Paykel Healthcare
15 Maurice Paykel Place
East Tamaki Auckland</address>
      <phone>+64 9 5740123 (Ext. 8822)</phone>
      <fax />
      <email>georgina.cuttance@fphcare.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Georgina Cuttance</name>
      <address>Fisher and Paykel Healthcare
15 Maurice Paykel Place
East Tamaki Auckland</address>
      <phone>+64 9 5740123 (Ext. 8822)</phone>
      <fax />
      <email>georgina.cuttance@fphcare.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>